Figure 1From: MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1 Positive (abnormal) immunohistochemical staining for p53 (left) and p16 (right) in urinary bladder carcinoma cells. Back to article page